Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUSTRATE: Torcetrapib/Atorvastatin in CHD
NCT00134173Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2003
- Countries
- 6
- Sponsor
- Pfizer
- Modality
- Small Molecules
- Drugs
- torcetrapib
- Conditions
- coronary heart disease (CHD)Coronary atherosclerosis (CAD)hyperlipidemia
01
Overview
Phase 3, randomised, double-blind trial of torcetrapib in coronary heart disease (CHD), Coronary atherosclerosis (CAD) and hyperlipidemia (2 arms), sponsored by Pfizer. Primary endpoint: Change in Percent Atheroma Volume at 24 months. Started Oct 2003; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Torcetrapib/Atorvastatin
Torcetrapib 60 mg + Atorvastatin (10-80 mg) QD
Atorvastatin
Atorvastatin (10-80 mg) QD + Placebo
03
Who it enrols
Patients with angiographically documented coronary heart disease and evidence of coronary atherosclerosis.
04
Endpoints
Primary
Change in Percent Atheroma Volume
Secondary
Changes in levels of lipids and other biomarkers
Beyond the preview
Go deeper on NCT00134173.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134173.